-
公开(公告)号：US20090117120A1
公开(公告)日：2009-05-07
申请号：US12157664
申请日：2008-06-11
申请人： Jan Grimm , Roger Nitsch , Marlen Knobloch , Uwe Konietzko , Markus Rudin , Thomas Muggler , Felicitas Kranz
发明人： Jan Grimm , Roger Nitsch , Marlen Knobloch , Uwe Konietzko , Markus Rudin , Thomas Muggler , Felicitas Kranz
IPC分类号： A61K39/395 , A01K67/027 , C12N15/85 , A61P25/28 , C12N15/12 , A61B10/00
CPC分类号： C07K14/4711 , A01K67/0275 , A01K2217/052 , A01K2227/105 , A01K2267/0312 , A61K39/0007 , C07K14/47 , C12N15/8509 , C12N2830/008 , C12N2830/85
摘要： Provided is a novel APP (amyloid precursor protein) transgenic non-human animal modeling in vivo the pathophysiological effects and effects on cognitive behavior of early intraneuronal and extracellular brain parenchymal amyloid-β (Aβ) deposition and cerebral amyloid angiopathy associated with brain microhemorrhages and reduced vasoreactivity and blood flow. Furthermore, methods of screening for therapeutic or diagnostic agents useful in the treatment or diagnosis of Alzheimer's disease, in particular for improving blood flow to the brain are provided as well as the corresponding therapeutic methods.
摘要翻译： 提供了一种新型的APP（淀粉样蛋白前体蛋白）转基因非人动物模型，体内对脑微量出血相关的早期神经元和细胞外脑实质淀粉样蛋白β（Abeta）沉积和脑淀粉样变性血管病的认知行为的病理生理作用和影响减少 血管活性和血流量。 此外，提供了可用于治疗或诊断阿尔茨海默氏病，特别是用于改善对脑的血流量的治疗或诊断剂的筛选方法以及相应的治疗方法。
-
公开(公告)号：US08022268B2
公开(公告)日：2011-09-20
申请号：US12157664
申请日：2008-06-11
申请人： Jan Grimm , Roger Nitsch , Marlen Knobloch , Uwe Konietzko , Markus Rudin , Thomas Müggler , Felicitas Kranz
发明人： Jan Grimm , Roger Nitsch , Marlen Knobloch , Uwe Konietzko , Markus Rudin , Thomas Müggler , Felicitas Kranz
IPC分类号： A01K67/027 , A01K67/00 , A01K67/033
CPC分类号： C07K14/4711 , A01K67/0275 , A01K2217/052 , A01K2227/105 , A01K2267/0312 , A61K39/0007 , C07K14/47 , C12N15/8509 , C12N2830/008 , C12N2830/85
摘要： Provided is a novel APP (amyloid precursor protein) transgenic non-human animal modeling in vivo the pathophysiological effects and effects on cognitive behavior of early intraneuronal and extracellular brain parenchymal amyloid-β (Aβ) deposition and cerebral amyloid angiopathy associated with brain microhemorrhages and reduced vasoreactivity and blood flow. Furthermore, methods of screening for therapeutic or diagnostic agents useful in the treatment or diagnosis of Alzheimer's disease, in particular for improving blood flow to the brain are provided as well as the corresponding therapeutic methods.
摘要翻译： 提供了一种新型APP（淀粉样蛋白前体蛋白）转基因非人动物体内模型，对早期神经元和细胞外脑实质淀粉样蛋白的认知行为的病理生理作用和影响。 （A＆BGR）沉积和与脑微出血相关的脑淀粉样血管病变，并减少血管反应性和血流量。 此外，提供了可用于治疗或诊断阿尔茨海默氏病，特别是用于改善对脑的血流量的治疗或诊断剂的筛选方法以及相应的治疗方法。
-
公开(公告)号：US08906367B2
公开(公告)日：2014-12-09
申请号：US12522031
申请日：2008-01-07
申请人： Roger Nitsch , Christoph Hock , Christoph Esslinger , Marlen Knobloch , Kathrin Tissot , Jan Grimm
发明人： Roger Nitsch , Christoph Hock , Christoph Esslinger , Marlen Knobloch , Kathrin Tissot , Jan Grimm
CPC分类号： C07K16/18 , A61K2039/505 , C07K16/00 , C07K2317/21 , C07K2317/77
摘要： Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.
摘要翻译： 提供了新型特异性结合分子，特别是人抗体以及其识别疾病相关蛋白的新表型的片段，衍生物和变体，其衍生自天然内源性蛋白质，但是在变体形式和/或出口的患者体内普遍存在 的正常生理环境。 此外，描述了包含这样的结合分子的药物组合物，其抗体及其模拟物以及筛选新结合分子的方法，其可以是或可以不是抗体以及治疗神经疾病如阿尔茨海默病的靶标。
-
公开(公告)号：US20150147343A1
公开(公告)日：2015-05-28
申请号：US14322096
申请日：2014-07-02
申请人： Roger NITSCH , Christoph Hock , Christoph Esslinger , Marlen Knobloch , Kathrin Tissot , Jan Grimm
发明人： Roger NITSCH , Christoph Hock , Christoph Esslinger , Marlen Knobloch , Kathrin Tissot , Jan Grimm
CPC分类号： C07K16/18 , A61K39/3955 , A61K45/06 , A61K51/1018 , A61K2039/505 , C07K16/00 , C07K2317/21 , C07K2317/30 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , G01N33/6854 , G01N33/6896 , G01N2333/4709 , G01N2800/2821 , G01N2800/52
摘要： Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.
摘要翻译： 提供了新型特异性结合分子，特别是人抗体以及其识别疾病相关蛋白的新表型的片段，衍生物和变体，其衍生自天然内源性蛋白质，但是在变体形式和/或出口的患者体内普遍存在 的正常生理环境。 此外，描述了包含这样的结合分子的药物组合物，其抗体及其模拟物以及筛选新结合分子的方法，其可以是或可以不是抗体以及治疗神经疾病如阿尔茨海默病的靶标。
-
公开(公告)号：US20100202968A1
公开(公告)日：2010-08-12
申请号：US12522031
申请日：2008-01-07
申请人： Roger Nitsch , Christoph Hock , Christoph Esslinger , Marlen Knobloch , Kathrin Tissot , Jan Grimm
发明人： Roger Nitsch , Christoph Hock , Christoph Esslinger , Marlen Knobloch , Kathrin Tissot , Jan Grimm
IPC分类号： A61K49/00 , G01N33/50 , C07K16/00 , C07H21/00 , C12N15/74 , C12N5/10 , C12P21/02 , A61K31/7088 , A61K35/12 , A61K39/395 , A61K39/00 , A61P25/28
CPC分类号： C07K16/18 , A61K2039/505 , C07K16/00 , C07K2317/21 , C07K2317/77
摘要： Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.
摘要翻译： 提供了新型特异性结合分子，特别是人抗体以及其识别疾病相关蛋白的新表型的片段，衍生物和变体，其衍生自天然内源性蛋白质，但是在变体形式和/或出口的患者体内普遍存在 的正常生理环境。 此外，描述了包含这样的结合分子的药物组合物，其抗体及其模拟物以及筛选新结合分子的方法，其可以是或可以不是抗体以及治疗神经疾病如阿尔茨海默病的靶标。
-
6.发明申请USE OF PHOSPHATASE INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES 审中-公开磷酸酯酶抑制剂用于治疗神经损伤性疾病的用途公开(公告)号：US20110086908A9
公开(公告)日：2011-04-14
申请号：US12524011
申请日：2008-01-22
IPC分类号： A61K31/352 , C12Q1/68 , A61P25/00
CPC分类号： G01N33/6896 , A01K67/0275 , A01K2217/05 , A01K2217/20 , A01K2227/105 , A01K2267/0312 , A61K31/341 , C12N15/8509 , G01N2333/916 , G01N2800/2821
摘要： Provided are novel a target and drugs in the treatment of neurological disorders related to amyloid beta pathology/amyloidosis. More specifically, the use of phosphatase inhibitors for the treatment of brain impairments mediated by Aβ-oligomers is described.
摘要翻译： 提供了一种靶向和药物治疗与淀粉样蛋白β病理学/淀粉样变性相关的神经障碍。 更具体地说，描述了使用磷酸酶抑制剂来治疗由Aβ寡聚物介导的脑损伤。
-
7.发明申请USE OF PHOSPHATASE INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES 审中-公开磷酸酯酶抑制剂用于治疗神经损伤性疾病的用途公开(公告)号：US20100048687A1
公开(公告)日：2010-02-25
申请号：US12524011
申请日：2008-07-22
IPC分类号： A61K31/352 , C12Q1/68 , A61P25/00
CPC分类号： G01N33/6896 , A01K67/0275 , A01K2217/05 , A01K2217/20 , A01K2227/105 , A01K2267/0312 , A61K31/341 , C12N15/8509 , G01N2333/916 , G01N2800/2821
摘要： Provided are novel a target and drugs in the treatment of neurological disorders related to amyloid beta pathology/amyloidosis. More specifically, the use of phosphatase inhibitors for the treatment of brain impairments mediated by Aβ-oligomers is described.
摘要翻译： 提供了一种靶向和药物治疗与淀粉样蛋白β病理学/淀粉样变性相关的神经障碍。 更具体地说，描述了使用磷酸酶抑制剂来治疗由Aβ寡聚物介导的脑损伤。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.032 秒)
